Lilly - Cymbalta: EMEA says "no"

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against extended approval for Eli Lilly's and Boehringer Ingelheim's Cymbalta as a treatment for fibromyalgia. The committee concluded that the effectiveness of the drug in treating the disease had not been sufficiently shown and that the treatment's benefits did not outweigh its risks.